Press Release
For Immediate Release
January 17, 2017
Contact: Chris Di Salvo, Professional Effects
E-mail: profeff@aol.com
Mobile: 408-506-0455
UCB Collaborates with Parkinson’s Institute and Clinical Center on Parkinson’s Insight Project
Collaboration aims to study drug treatment for patients living with Parkinson’s Disease
Sunnyvale, CA – January17, 2017 – UCB and the Parkinson’s Institute and Clinical Center announced today a strategic alliance to advance the understanding of medications used to treat Parkinson’s outside of a controlled clinical trial setting.
As developers of NEUPRO® (rotigotine transdermal system), a 24 hour time release patch which provides people with Parkinson’s Disease continuous and stable delivery of their medication, UCB is well placed to collaborate with the Parkinson’s Institute to improve knowledge and awareness of real world medication use.
“We are very excited to partner with UCB. Ideally, this study will help us deliver optimal healthcare for people living with Parkinson’s,” said Dr. Carrolee Barlow, CEO, Parkinson’s Institute and Clinical Center. “The Parkinson’s Insight project brings to bear cutting edge semantic technology to allow us to pull together our clinical medical record data to ask key questions about important healthcare problems at a fraction of the cost that would be required without utilizing the technology,”
Parkinson’s is a progressive movement-related disorder of the central nervous system. It is estimated that there are approximately one million Americans living with Parkinson’s. Each year, 50,000 new cases are diagnosed, and this rate is expected to rise with the aging population. A clear understanding of Parkinson’s and its underlying pathophysiology continues to be elusive as a result of the disease’s complexity.
About Parkinson’s Institute & Clinical Center:
The Parkinson’s institute and Clinical Center is America’s only independent non-profit organization combining world-class care, clinical research, laboratory research, and clinical studies for Parkinson’s disease under one roof. They have been thought leaders, pioneers and innovators in the area of Parkinson’s research and care for more than 30 years. Dr. J. William Langston, a world-renowned neurologist, and a distinguished group of researchers ignited the Parkinson’s research field 30 years ago and founded the Institute to change the course of Parkinson’s research. Since that pivotal moment, they have been instrumental in the evolving course of care, research and drug development for Parkinson’s disease and other related movement disorders. Now under the direction of recently appointed CEO, Carrolee Barlow, MD, PhD, the Institute will continue its legacy of being at the forefront of discovering and developing the latest, most innovative treatments and therapies for people living with Parkinson’s. For more information visit www.thepi.org or call (408) 734-2800
About UCB:
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of € 3.88 billion in 2015. UCB is listed on Euronext Brussels (ticker: UCB). Find more information at www.ucb.com.